$RSLS
ReShape Lifesciences Inc. Stock $rsls

$rsls Overview Financials Valuation SEC Filings Company Website

2019 Q3 Form 10-Q Financial Statement

#000142757019000083 Filed on July 24, 2019

Income Statement

Concept	2019 Q3	2019 Q2	2018 Q2
Revenue	$333.0K	$386.0K	$2.732M
YoY Change	-88.85%	-85.87%	39.17%
Cost Of Revenue	$412.0K	$679.0K	$1.732M
YoY Change	-70.94%	-60.8%	74.95%
Gross Profit	-$79.00K	-$293.0K	$1.000M
YoY Change	-105.04%	-129.3%	2.77%
Gross Profit Margin	-23.72%	-75.91%	36.6%
Selling, General & Admin	$2.489M	$4.332M	$7.250M
YoY Change	-57.35%	-40.25%	23.87%
% of Gross Profit			725.0%
Research & Development	$1.174M	$1.788M	$3.352M
YoY Change	-50.42%	-46.66%	21.45%
% of Gross Profit			335.2%
Depreciation & Amortization	$422.0K	$430.0K	$1.390M
YoY Change	-47.25%	-69.06%	3375.0%
% of Gross Profit			139.0%
Operating Expenses	$3.663M	$6.120M	$10.60M
YoY Change	-55.35%	-42.28%	23.09%
Operating Profit	-$3.742M	-$6.413M	-$9.602M
YoY Change	-43.6%	-33.21%	25.68%
Interest Expense	$37.00K	-$295.0K	-$57.00K
YoY Change	-152.86%	417.54%	62.86%
% of Operating Profit
Other Income/Expense, Net	-$1.000K	-$59.00K	-$94.00K
YoY Change	-97.5%	-37.23%	70.91%
Pretax Income	-$28.75M	-$16.51M	-$20.52M
YoY Change	443.86%	-19.56%	200.0%
Income Tax	$0.00	-$586.0K	-$1.210M
% Of Pretax Income
Net Earnings	-$3.706M	-$6.767M	-$9.753M
YoY Change	-45.06%	-30.62%	26.17%
Net Earnings / Revenue	-1112.91%	-1753.11%	-356.99%
Basic Earnings Per Share
Diluted Earnings Per Share	-$106.4M	-$150.2M	-$156.4B
COMMON SHARES
Basic Shares Outstanding	35.58M shares	24.00M shares	17.57M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2019 Q3	2019 Q2	2018 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$7.717M	$4.355M	$1.860M
YoY Change	1531.95%	134.14%	-83.39%
Cash & Equivalents	$19.40M	$13.51M	$24.21M
Short-Term Investments	$0.00	$0.00	$1.000M
Other Short-Term Assets	$683.0K	$954.0K	$857.0K
YoY Change	-24.86%	11.32%	21.56%
Inventory	$2.048M	$2.107M	$1.842M
Prepaid Expenses	$656.0K	$954.0K	$734.0K
Receivables	$238.0K	$447.0K	$3.049M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$22.35M	$17.02M	$30.96M
YoY Change	-36.7%	-45.02%	-51.58%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.117M	$1.038M	$1.514M
YoY Change	-28.94%	-31.44%	45.02%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$586.0K	$563.0K	$80.00K
YoY Change	616.73%	603.75%	-89.04%
Total Long-Term Assets	$2.308M	$2.178M	$1.514M
YoY Change	46.82%	43.86%	45.02%
TOTAL ASSETS
Total Short-Term Assets	$22.35M	$17.02M	$30.96M
Total Long-Term Assets	$2.308M	$2.178M	$1.514M
Total Assets	$24.66M	$19.20M	$32.47M
YoY Change	-33.14%	-40.87%	-50.03%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$732.0K	$1.082M	$1.445M
YoY Change	-49.79%	-25.12%	30.18%
Accrued Expenses	$5.876M	$343.0K	$4.500M
YoY Change	33.28%	-92.38%	32.35%
Deferred Revenue	$283.0K	$320.0K	$302.0K
YoY Change	-5.98%	5.96%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$5.000M	$3.965M
YoY Change	-100.0%	26.1%
Total Short-Term Liabilities	$3.905M	$10.09M	$10.40M
YoY Change	-46.37%	-2.94%	115.82%
LONG-TERM LIABILITIES
Long-Term Debt	$4.579M	$0.00	$5.980M
YoY Change	-51.28%	-100.0%	-39.6%
Other Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change	-100.0%		-100.0%
Total Long-Term Liabilities	$687.0K	$722.0K	$6.024M
YoY Change	-92.73%	-88.01%	-39.4%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.905M	$10.09M	$10.40M
Total Long-Term Liabilities	$687.0K	$722.0K	$6.024M
Total Liabilities	$4.592M	$10.81M	$16.42M
YoY Change	-72.55%	-34.15%	11.27%
SHAREHOLDERS EQUITY
Retained Earnings	-$167.5M	-$163.8M	-$133.3M
YoY Change	19.64%	22.88%	44.73%
Common Stock	$187.6M	$172.2M	$149.3M
YoY Change	17.13%	15.33%	4.9%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$20.07M	$8.376M	$16.05M
YoY Change
Total Liabilities & Shareholders Equity	$24.66M	$19.20M	$32.47M
YoY Change	-33.14%	-40.87%	-50.03%

Cashflow Statement

Concept	2019 Q3	2019 Q2	2018 Q2
OPERATING ACTIVITIES
Net Income	-$3.706M	-$6.767M	-$9.753M
YoY Change	-45.06%	-30.62%	26.17%
Depreciation, Depletion And Amortization	$422.0K	$430.0K	$1.390M
YoY Change	-47.25%	-69.06%	3375.0%
Cash From Operating Activities	-$4.280M	-$2.900M	-$6.500M
YoY Change	-6.56%	-55.38%	15.04%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00	-$10.00K
YoY Change	-100.0%	-100.0%	0.0%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	-$990.0K
YoY Change		-100.0%	-46.49%
Cash From Investing Activities	$0.00	$0.00	-$10.00K
YoY Change	-100.0%	-100.0%	-99.46%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	7.651M	5.427M	7.530M
YoY Change	140.05%	-27.93%	37550.0%
NET CHANGE
Cash From Operating Activities	-4.280M	-2.900M	-6.500M
Cash From Investing Activities	0.000	0.000	-10.00K
Cash From Financing Activities	7.651M	5.427M	7.530M
Net Change In Cash	3.371M	2.527M	1.020M
YoY Change	-342.46%	147.75%	-113.64%
FREE CASH FLOW
Cash From Operating Activities	-$4.280M	-$2.900M	-$6.500M
Capital Expenditures	$0.00	$0.00	-$10.00K
Free Cash Flow	-$4.280M	-$2.900M	-$6.490M
YoY Change	-6.76%	-55.32%	15.07%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2019
	dei	Document Period End Date DocumentPeriodEndDate	2019-06-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001427570
CY2019Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	35582614	shares
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	OBALON THERAPEUTICS INC
	dei	Entity Shell Company EntityShellCompany	false
	dei	Entity Small Business EntitySmallBusiness	true
CY2018Q4	obln	Accrued Customer Incentives Current AccruedCustomerIncentivesCurrent	467000	USD
CY2019Q2	obln	Accrued Customer Incentives Current AccruedCustomerIncentivesCurrent	362000	USD
CY2018Q4	obln	Accrued Legal And Professional Fees Current AccruedLegalAndProfessionalFeesCurrent	624000	USD
CY2019Q2	obln	Accrued Legal And Professional Fees Current AccruedLegalAndProfessionalFeesCurrent	960000	USD
CY2019Q2	obln	Cash And Cash Equivalents Available For Use CashAndCashEquivalentsAvailableForUse	8500000	USD
CY2019Q2	obln	Cash Minimum Before Possible Default CashMinimumBeforePossibleDefault	5000000	USD
	obln	Increase Decrease In Lease Liabilities IncreaseDecreaseInLeaseLiabilities	-136000	USD
CY2019Q2	obln	Lease Liability Current LeaseLiabilityCurrent	468000	USD
CY2019Q2	obln	Lease Liability Noncurrent LeaseLiabilityNoncurrent	722000	USD
CY2019Q2	obln	Lease Right Of Use Asset LeaseRightOfUseAsset	1140000	USD
	obln	Operating Lease Rightof Use Asset Amortization OperatingLeaseRightofUseAssetAmortization	186000	USD
	obln	Restructuring Charges Gross RestructuringChargesGross	1105000	USD
CY2019Q2	obln	Sharebased Compensation Arrangementby Sharebased Payment Award Non Option Equity Instruments Vestedand Expectedto Vest Outstanding Aggregate Intrinsic Value SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsVestedandExpectedtoVestOutstandingAggregateIntrinsicValue	56000	USD
CY2019Q2	obln	Sharebased Compensation Arrangementby Sharebased Payment Award Non Option Equity Instruments Vestedand Expectedto Vest Outstanding Number SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsVestedandExpectedtoVestOutstandingNumber	79653	shares
CY2019Q2	obln	Sharebased Compensation Arrangementby Sharebased Payment Award Non Option Equity Instruments Vestedand Expectedto Vest Outstanding Weighted Average Exercise Price SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsVestedandExpectedtoVestOutstandingWeightedAverageExercisePrice	2.30
	obln	Unpaid Stock Issuance Costs UnpaidStockIssuanceCosts	0	USD
	obln	Unpaid Stock Issuance Costs UnpaidStockIssuanceCosts	377000	USD
CY2018Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1159000	USD
CY2019Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	1082000	USD
CY2018Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	870000	USD
CY2019Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	447000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	7000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	2000	USD
CY2018Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1979000	USD
CY2019Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2107000	USD
CY2018Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	161838000	USD
CY2019Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	172162000	USD
CY2018Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	14000	USD
CY2018Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	15000	USD
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	14000	USD
CY2019Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	15000	USD
CY2018Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1389000	USD
CY2018Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1214000	USD
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1105000	USD
CY2019Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	536000	USD
CY2018Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	665000	USD
CY2019Q2	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	900000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	22000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	70000	USD
CY2018Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	383264	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	492351	shares
CY2019Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	0	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	112892	shares
CY2018Q4	us-gaap	Assets Assets	30386000	USD
CY2019Q2	us-gaap	Assets Assets	19199000	USD
CY2018Q4	us-gaap	Assets Current AssetsCurrent	28647000	USD
CY2019Q2	us-gaap	Assets Current AssetsCurrent	17021000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	106000	USD
CY2018Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-9753000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-21873000	USD
CY2019Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-6767000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-15057000	USD
CY2018Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	352000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	USD
CY2019Q2	us-gaap	Capitalized Contract Cost Amortization Period CapitalizedContractCostAmortizationPeriod	P1Y
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	21187000	USD
CY2019Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	13513000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	21108000	USD
CY2018Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	24212000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	21187000	USD
CY2019Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	13513000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	3104000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-7674000	USD
CY2018Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q2	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	6539115	shares
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2019Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2019Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	23513292	shares
CY2019Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	35582614	shares
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	23513292	shares
CY2019Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	35582614	shares
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	23285112	shares
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	23000	USD
CY2019Q2	us-gaap	Common Stock Value CommonStockValue	36000	USD
CY2019Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	320000	USD
CY2018Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1732000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2501000	USD
CY2019Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	679000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1911000	USD
CY2019Q2	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	5000000	USD
CY2019Q2	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	0	USD
CY2018Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	200000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	300000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	276000	USD
CY2019Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	100000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	256000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	300000	USD
CY2018Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.57
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.29
CY2019Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.25
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.60
CY2018Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3805000	USD
CY2019Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1093000	USD
CY2019Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	2400000	USD
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y7M15D
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-107000	USD
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-95000	USD
CY2018Q2	us-gaap	Gross Profit GrossProfit	1000000	USD
	us-gaap	Gross Profit GrossProfit	1577000	USD
CY2019Q2	us-gaap	Gross Profit GrossProfit	-293000	USD
	us-gaap	Gross Profit GrossProfit	250000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	275000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-191000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1174000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-423000	USD
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-208000	USD
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-32000	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-2362000	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-2712000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	424000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	157000	USD
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-857000	USD
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-1760000	USD
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	842000	USD
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-142000	USD
CY2018Q2	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-57000	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-94000	USD
CY2019Q2	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-295000	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-485000	USD
	us-gaap	Interest Paid Net InterestPaidNet	307000	USD
	us-gaap	Interest Paid Net InterestPaidNet	563000	USD
CY2018Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	12000	USD
CY2019Q2	us-gaap	Interest Receivable Current InterestReceivableCurrent	0	USD
CY2018Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	202000	USD
CY2019Q2	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	155000	USD
CY2018Q4	us-gaap	Inventory Net InventoryNet	1580000	USD
CY2019Q2	us-gaap	Inventory Net InventoryNet	2107000	USD
CY2018Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	1090000	USD
CY2019Q2	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	1870000	USD
CY2018Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	288000	USD
CY2019Q2	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	82000	USD
CY2018Q2	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	100000	USD
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	200000	USD
CY2019Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1313000	USD
CY2019Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	117000	USD
CY2019Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	488000	USD
CY2019Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	475000	USD
CY2019Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	233000	USD
CY2019Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	123000	USD
CY2018Q4	us-gaap	Liabilities Liabilities	17279000	USD
CY2019Q2	us-gaap	Liabilities Liabilities	10812000	USD
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	30386000	USD
CY2019Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	19199000	USD
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	17231000	USD
CY2019Q2	us-gaap	Liabilities Current LiabilitiesCurrent	10090000	USD
CY2018Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	48000	USD
CY2019Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	722000	USD
CY2019Q2	us-gaap	Long Term Debt LongTermDebt	5000000	USD
CY2018Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	9930000	USD
CY2019Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	5000000	USD
CY2019Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	0	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	179000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3794000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	21649000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	2530000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-18724000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-13998000	USD
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	-12126000	USD
CY2018Q2	us-gaap	Net Income Loss NetIncomeLoss	-9753000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-21879000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-8290000	USD
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-6767000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-15057000	USD
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2018Q2	us-gaap	Operating Expenses OperatingExpenses	10602000	USD
	us-gaap	Operating Expenses OperatingExpenses	23247000	USD
CY2019Q2	us-gaap	Operating Expenses OperatingExpenses	6120000	USD
	us-gaap	Operating Expenses OperatingExpenses	14763000	USD
CY2018Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-9602000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-21670000	USD
CY2019Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-6413000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-14513000	USD
CY2019Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	100000	USD
	us-gaap	Operating Lease Cost OperatingLeaseCost	200000	USD
CY2019Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	1190000	USD
CY2019Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	468000	USD
CY2019Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	722000	USD
CY2019Q2	us-gaap	Operating Lease Payments OperatingLeasePayments	100000	USD
	us-gaap	Operating Lease Payments OperatingLeasePayments	200000	USD
CY2019Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.070
CY2019Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y10M
CY2018Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	762000	USD
CY2019Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	686000	USD
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	0	USD
CY2018Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	2329000	USD
CY2019Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	954000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	8793000	USD
CY2018Q4	us-gaap	Other Assets Current OtherAssetsCurrent	2462000	USD
CY2019Q2	us-gaap	Other Assets Current OtherAssetsCurrent	954000	USD
CY2018Q4	us-gaap	Other Assets Miscellaneous Current OtherAssetsMiscellaneousCurrent	121000	USD
CY2019Q2	us-gaap	Other Assets Miscellaneous Current OtherAssetsMiscellaneousCurrent	0	USD
CY2018Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	6000	USD
CY2018Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	0	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	6000	USD
CY2019Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	0	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	0	USD
CY2018Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1985000	USD
CY2019Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	2127000	USD
CY2018Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	48000	USD
CY2019Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	0	USD
CY2018Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-94000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-115000	USD
CY2019Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-59000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-59000	USD
	us-gaap	Payments For Restructuring PaymentsForRestructuring	537000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	657000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	20000	USD
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	995000	USD
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	USD
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	10000000	USD
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	23301000	USD
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	2550000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	31000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1000	USD
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	148000	USD
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	0	USD
CY2018Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3718000	USD
CY2019Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3145000	USD
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1739000	USD
CY2019Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1038000	USD
CY2019Q2	us-gaap	Purchase Commitment Remaining Minimum Amount Committed PurchaseCommitmentRemainingMinimumAmountCommitted	1500000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	15000000	USD
CY2018Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3352000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5991000	USD
CY2019Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1788000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4227000	USD
CY2019Q2	us-gaap	Restructuring And Related Cost Number Of Positions Eliminated RestructuringAndRelatedCostNumberOfPositionsEliminated	49	employee
CY2019Q2	us-gaap	Restructuring And Related Cost Number Of Positions Eliminated Period Percent RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent	0.50
CY2019Q2	us-gaap	Restructuring Charges RestructuringCharges	1100000	USD
CY2019Q2	us-gaap	Restructuring Charges RestructuringCharges	1099000	USD
	us-gaap	Restructuring Charges RestructuringCharges	1099000	USD
CY2018Q4	us-gaap	Restructuring Reserve RestructuringReserve	0	USD
CY2019Q2	us-gaap	Restructuring Reserve RestructuringReserve	568000	USD
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-148754000	USD
CY2019Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-163811000	USD
CY2019Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-163800000	USD
CY2018Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2732000	USD
CY2018Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2700000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	4100000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	4078000	USD
CY2019Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	400000	USD
CY2019Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	386000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2161000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2200000	USD
	us-gaap	Revenue Performance Obligation Description Of Timing RevenuePerformanceObligationDescriptionOfTiming	three to six months
CY2018Q4	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	132000	USD
CY2019Q2	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	119000	USD
CY2018Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	7250000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	17256000	USD
CY2019Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	4332000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	10536000	USD
CY2018Q2	us-gaap	Share Based Compensation ShareBasedCompensation	1215000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	2603000	USD
CY2019Q2	us-gaap	Share Based Compensation ShareBasedCompensation	536000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1641000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	228739	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1019615	shares
CY2019Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	USD
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3360048	shares
CY2019Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4149743	shares
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.83
CY2019Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.98
CY2019Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	0	USD
CY2019Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	2485077	shares
CY2019Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	5.29
CY2019Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	0	USD
CY2019Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	3811354	shares
CY2019Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	5.09
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.87
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	4.89
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.15
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y3M8D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P6Y3M0D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P6Y3M6D
CY2018Q4	us-gaap	Short Term Investments ShortTermInvestments	2548000	USD
CY2019Q2	us-gaap	Short Term Investments ShortTermInvestments	0	USD
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1181	shares
CY2019Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	26877568	shares
CY2018Q2	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	148000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	581000	USD
CY2019Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	8085000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures	0	USD
CY2019Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures	0	USD
CY2018Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	USD
CY2018Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	USD
CY2018Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	28000	USD
CY2018Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	3000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1000	USD
CY2019Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	0	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	13107000	USD
CY2019Q2	us-gaap	Stockholders Equity StockholdersEquity	8387000	USD
CY2017Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	35113000	USD
CY2018Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	24424000	USD
CY2018Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	16051000	USD
CY2018Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	13107000	USD
CY2019Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	6518000	USD
CY2019Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	8387000	USD
CY2018Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	17039876	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	17013529	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	25005475	shares
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentrations of Credit Risk </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash equivalents and trade accounts receivable, which are generally not collateralized. The Company limits its exposure to credit loss by placing its cash equivalents with high credit quality financial institutions and investing in high quality short-term debt instruments. The Company’s customers consist of physicians and institutions in the United States and one international distributor. The Company establishes customer credit policies related to its accounts receivable based on historical collection experiences within the various markets in which the Company operates, historical past-due amounts, and any specific information that the Company becomes aware of such as bankruptcy or liquidity issues of customers. </font></div></div>
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Reported amounts and note disclosures reflect the overall economic conditions that are most likely to occur and anticipated measures management intends to take. Actual results could differ materially from those estimates. All revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.</font></div></div>

Files In Submission

Name	View Source	Status
0001427570-19-000083-index-headers.html	Edgar Link	pending
0001427570-19-000083-index.html	Edgar Link	pending
0001427570-19-000083.txt	Edgar Link	pending
0001427570-19-000083-xbrl.zip	Edgar Link	pending
ex102-macdonaldofferletter.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
obln-20190630.xml	Edgar Link	completed
obln-20190630.xsd	Edgar Link	pending
obln-20190630_cal.xml	Edgar Link	unprocessable
obln-20190630_def.xml	Edgar Link	unprocessable
obln-20190630_lab.xml	Edgar Link	unprocessable
obln-20190630_pre.xml	Edgar Link	unprocessable
obln-63019x10q.htm	Edgar Link	pending
obln101-obalonxconsultinga.htm	Edgar Link	pending
obln311-63019.htm	Edgar Link	pending
obln321-63019.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RSLS
ReShape Lifesciences Inc. Stock $rsls

2019 Q3 Form 10-Q Financial Statement

#000142757019000083 Filed on July 24, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RSLS ReShape Lifesciences Inc. Stock $rsls

2019 Q3 Form 10-Q Financial Statement

#000142757019000083 Filed on July 24, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RSLS
ReShape Lifesciences Inc. Stock $rsls